Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Oct;30(4):501–510. doi: 10.1111/j.1365-2125.1990.tb03807.x

Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow?

T Pullar 1
PMCID: PMC1368239  PMID: 2291864

Full text

PDF
510

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ash G., Baker R., Rajapakse C., Swinson D. R. Study of sulphamethoxazole in rheumatoid arthritis. Br J Rheumatol. 1986 Aug;25(3):285–287. doi: 10.1093/rheumatology/25.3.285. [DOI] [PubMed] [Google Scholar]
  2. Belch J. J., Madhok R., McArdle B., McLaughlin K., Kluft C., Forbes C. D., Sturrock R. D. The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol. Q J Med. 1986 Jan;58(225):19–27. [PubMed] [Google Scholar]
  3. Bird H. A., Burkinshaw L., Pearson D., Atkinson P. J., Leatham P. A., Hill J., Raven A., Wright V. A controlled trial of nandrolone decanoate in the treatment of rheumatoid arthritis in postmenopausal women. Ann Rheum Dis. 1987 Mar;46(3):237–243. doi: 10.1136/ard.46.3.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bird H. A., Hill J., Sitton N. G., Dixon J. S., Wright V. A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis. Clin Rheumatol. 1988 Mar;7(1):91–94. doi: 10.1007/BF02284063. [DOI] [PubMed] [Google Scholar]
  5. Bird H. A., Hill J., Sitton N. G., Dixon J. S., Wright V. A clinical and biochemical evaluation of etretinate in rheumatoid arthritis. Rheumatol Int. 1988;8(2):55–59. doi: 10.1007/BF00271835. [DOI] [PubMed] [Google Scholar]
  6. Bird H. A., Le Gallez P., Dixon J. S., Catalano M. A., Traficante A., Liauw L. A., Sussman H., Rotman H., Wright V. A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritis. J Rheumatol. 1990 May;17(5):603–608. [PubMed] [Google Scholar]
  7. Borg G., Allander E., Lund B., Berg E., Brodin U., Pettersson H., Trang L. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J Rheumatol. 1988 Dec;15(12):1747–1754. [PubMed] [Google Scholar]
  8. British Society for Rheumatology. Third annual general meeting. London, 19-22 November 1986. Abstracts. Br J Rheumatol. 1986;25 (Suppl 2):114–abstracts. [PubMed] [Google Scholar]
  9. Bunch T. W., O'Duffy J. D., Tompkins R. B., O'Fallon W. M. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum. 1984 Mar;27(3):267–276. doi: 10.1002/art.1780270304. [DOI] [PubMed] [Google Scholar]
  10. Cannon G. W., Pincus S. H., Emkey R. D., Denes A., Cohen S. A., Wolfe F., Saway P. A., Jaffer A. M., Weaver A. L., Cogen L. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 1989 Aug;32(8):964–973. doi: 10.1002/anr.1780320805. [DOI] [PubMed] [Google Scholar]
  11. Dixon J. S., Bird H. A., Pickup M. E., Wright V. A human model screening system for the detection of specific antirheumatic activity. Semin Arthritis Rheum. 1982 Nov;12(2):185–190. doi: 10.1016/0049-0172(82)90059-2. [DOI] [PubMed] [Google Scholar]
  12. Dixon J. S., Bird H. A., Surrall K. E., Sitton N. G., Wright V. A comparison of therapies which may influence trace metals in rheumatoid arthritis. Clin Rheumatol. 1984 Dec;3(4):451–457. doi: 10.1007/BF02031267. [DOI] [PubMed] [Google Scholar]
  13. Dougados M., Awada H., Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis. 1988 Feb;47(2):127–133. doi: 10.1136/ard.47.2.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Egsmose C., Lund B., Andersen R. B. Timegadine: more than a non-steroidal for the treatment of rheumatoid arthritis. A controlled, double-blind study. Scand J Rheumatol. 1988;17(2):103–111. doi: 10.3109/03009748809098769. [DOI] [PubMed] [Google Scholar]
  15. FREEDMAN A. Chloroquine and rheumatoid arthritis; a short-term controlled trial. Ann Rheum Dis. 1956 Sep;15(3):251–257. doi: 10.1136/ard.15.3.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fraser T. N. Gold Treatment in Rheumatoid Arthritis. Ann Rheum Dis. 1945 Jun;4(4):71–75. doi: 10.1136/ard.4.4.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Furst D. E. Rational use of disease-modifying antirheumatic drugs. Drugs. 1990 Jan;39(1):19–37. doi: 10.2165/00003495-199039010-00003. [DOI] [PubMed] [Google Scholar]
  18. Grimaldi M. G. Long-term low dose haloperidol treatment in rheumatoid patients: effects on serum sulphydryl levels, technetium index, ESR, and clinical response. Br J Clin Pharmacol. 1981 Oct;12(4):579–581. doi: 10.1111/j.1365-2125.1981.tb01268.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gutiérrez-Rodríguez O., Starusta-Bacal P., Gutiérrez-Montes O. Treatment of refractory rheumatoid arthritis--the thalidomide experience. J Rheumatol. 1989 Feb;16(2):158–163. [PubMed] [Google Scholar]
  20. HAMILTON E. B., SCOTT J. T. Hydroxychloroquine sulfate ("plaguenil") in treatment of rheumatoid arthritis. Arthritis Rheum. 1962 Oct;5:502–512. doi: 10.1002/art.1780050507. [DOI] [PubMed] [Google Scholar]
  21. Hauzeur J. P., Appelboom T. Double-blind, placebo-controlled study of OM-8980 in rheumatoid arthritis. Rheumatol Int. 1989;9(2):71–76. doi: 10.1007/BF00270248. [DOI] [PubMed] [Google Scholar]
  22. Healey L. A., Wilske K. R. Reforming the pyramid. A plan for treating rheumatoid arthritis in the 1990s. Rheum Dis Clin North Am. 1989 Aug;15(3):615–619. [PubMed] [Google Scholar]
  23. Hess E. V., Luggen M. E. Remodeling the pyramid--a concept whose time has not yet come. J Rheumatol. 1989 Sep;16(9):1175–1176. [PubMed] [Google Scholar]
  24. Kirwan J. R., Chaput de Saintonge D. M., Joyce C. R., Currey H. L. Clinical judgment in rheumatoid arthritis. III. British rheumatologists' judgments of 'change in response to therapy'. Ann Rheum Dis. 1984 Oct;43(5):686–694. doi: 10.1136/ard.43.5.686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Martin M. F., Surrall K. E., McKenna F., Dixon J. S., Bird H. A., Wright V. Captopril: a new treatment for rheumatoid arthritis? Lancet. 1984 Jun 16;1(8390):1325–1328. doi: 10.1016/s0140-6736(84)91821-x. [DOI] [PubMed] [Google Scholar]
  26. McConkey B., Amos R. S., Butler E. P., Crockson R. A., Crockson A. P., Walsh L. Salazopyrin in rheumatoid arthritis. Agents Actions. 1978 Jun;8(4):438–441. doi: 10.1007/BF01968673. [DOI] [PubMed] [Google Scholar]
  27. McConkey B., Davies P., Crockson R. A., Crockson A. P., Butler M., Constable T. J. Dapsone in rheumatoid arthritis. Rheumatol Rehabil. 1976 Aug;15(3):230–234. doi: 10.1093/rheumatology/15.3.230. [DOI] [PubMed] [Google Scholar]
  28. McConkey B., Situnayake R. D. Effects of rifampicin with and without isoniazid in rheumatoid arthritis. J Rheumatol. 1988 Jan;15(1):46–50. [PubMed] [Google Scholar]
  29. Mortiboy D., Palmer R. G. Ciprofloxacin and rheumatoid arthritis--lack of effect. Br J Rheumatol. 1989 Jun;28(3):272–272. doi: 10.1093/rheumatology/28.3.272. [DOI] [PubMed] [Google Scholar]
  30. Neumann V. C., Taggart A. J., Le Gallez P., Astbury C., Hill J., Bird H. A. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J Rheumatol. 1986 Apr;13(2):285–287. [PubMed] [Google Scholar]
  31. Nuki G. Non-steroidal analgesic and anti-inflammatory agents. Br Med J (Clin Res Ed) 1983 Jul 2;287(6384):39–43. doi: 10.1136/bmj.287.6384.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. PAGE F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951 Oct 27;2(6687):755–758. doi: 10.1016/s0140-6736(51)91643-1. [DOI] [PubMed] [Google Scholar]
  33. Pasero G., Pellegrini P., Ambanelli U., Ciompi M. L., Colamussi V., Ferraccioli G., Barbieri P., Mazzoni M. R., Menegale G., Trippi D. Controlled multicenter trial of tiopronin and d-penicillamine for rheumatoid arthritis. Arthritis Rheum. 1982 Aug;25(8):923–929. doi: 10.1002/art.1780250803. [DOI] [PubMed] [Google Scholar]
  34. Pattrick M., Heptinstall S., Doherty M. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Ann Rheum Dis. 1989 Jul;48(7):547–549. doi: 10.1136/ard.48.7.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Polson R. J., Jawad A. S., Bomford A., Berry H., Williams R. Treatment of rheumatoid arthritis with desferrioxamine. Q J Med. 1986 Dec;61(236):1153–1158. [PubMed] [Google Scholar]
  36. Pullar T., Capell H. A. A rheumatological dilemma: is it possible to modify the course of rheumatoid arthritis? Can we answer the question? Ann Rheum Dis. 1985 Feb;44(2):134–140. doi: 10.1136/ard.44.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Pullar T., Capell H. A. Selection of suitable patients for second-line therapy in rheumatoid arthritis. Br J Rheumatol. 1986 Aug;25(3):276–281. doi: 10.1093/rheumatology/25.3.276. [DOI] [PubMed] [Google Scholar]
  38. Pullar T., Hunter J. A., Capell H. A. Does second-line therapy affect the radiological progression of rheumatoid arthritis? Ann Rheum Dis. 1984 Feb;43(1):18–23. doi: 10.1136/ard.43.1.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Pullar T., Hunter J. A., Capell H. A. Second line therapy in rheumatoid arthritis--a four year prospective study. Clin Rheumatol. 1985 Jun;4(2):133–142. doi: 10.1007/BF02032283. [DOI] [PubMed] [Google Scholar]
  40. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1102–1104. doi: 10.1136/bmj.287.6399.1102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br J Rheumatol. 1985 Aug;24(3):269–276. doi: 10.1093/rheumatology/24.3.269. [DOI] [PubMed] [Google Scholar]
  42. Pullar T., Hunter J. A., Capell H. A. Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J (Clin Res Ed) 1985 May 25;290(6481):1535–1538. doi: 10.1136/bmj.290.6481.1535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Pullar T., Peaker S., Martin M. F., Bird H. A., Feely M. P. The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Br J Rheumatol. 1988 Oct;27(5):381–384. doi: 10.1093/rheumatology/27.5.381. [DOI] [PubMed] [Google Scholar]
  44. Ralston S. H., Hacking L., Willocks L., Bruce F., Pitkeathly D. A. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis. 1989 May;48(5):396–399. doi: 10.1136/ard.48.5.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Richards I. M., Fraser S. M., Hunter J. A., Capell H. A. Comparison of phenytoin and gold as second line drugs in rheumatoid arthritis. Ann Rheum Dis. 1987 Sep;46(9):667–669. doi: 10.1136/ard.46.9.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. SIEVERS K., HURRI L. Combined therapy of rheumatoid arthritis with gold and chloroquine. I. Evaluation of the therapeutic effect. Acta Rheumatol Scand. 1963;9:48–55. [PubMed] [Google Scholar]
  47. Scott D. L., Dacre J. E., Greenwood A., Treasure L., Huskisson E. C. Can we develop simple response criteria for slow acting antirheumatic drugs? Ann Rheum Dis. 1990 Mar;49(3):196–198. doi: 10.1136/ard.49.3.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Scott D. L., Spector T. D., Pullar T., McConkey B. What should we hope to achieve when treating rheumatoid arthritis? Ann Rheum Dis. 1989 Mar;48(3):256–261. doi: 10.1136/ard.48.3.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Sinclair R. J., Duthie J. J. Salazopyrin in the Treatment of Rheumatoid Arthritis. Ann Rheum Dis. 1949 Sep;8(3):226–231. doi: 10.1136/ard.8.3.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Situnayake R. D., Grindulis K. A., McConkey B. Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis. 1987 Mar;46(3):177–183. doi: 10.1136/ard.46.3.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Spector T. D., Thompson P. W., Evans S. J., Scott P. L. Are slow-acting antirheumatic drugs being given earlier in rheumatoid arthritis? Br J Rheumatol. 1988 Dec;27(6):498–499. doi: 10.1093/rheumatology/27.6.498. [DOI] [PubMed] [Google Scholar]
  52. Taggart A. J., Hill J., Astbury C., Dixon J. S., Bird H. A., Wright V. Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis. Br J Rheumatol. 1987 Feb;26(1):32–36. doi: 10.1093/rheumatology/26.1.32. [DOI] [PubMed] [Google Scholar]
  53. WALSHE J. M. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956 Oct;21(4):487–495. doi: 10.1016/0002-9343(56)90066-3. [DOI] [PubMed] [Google Scholar]
  54. Weinblatt M. E., Coblyn J. S., Fraser P. A., Anderson R. J., Spragg J., Trentham D. E., Austen K. F. Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum. 1987 Jan;30(1):11–17. doi: 10.1002/art.1780300102. [DOI] [PubMed] [Google Scholar]
  55. Weiss M. M. Corticosteroids in rheumatoid arthritis. Semin Arthritis Rheum. 1989 Aug;19(1):9–21. doi: 10.1016/0049-0172(89)90083-8. [DOI] [PubMed] [Google Scholar]
  56. Williamson M. P., Humm G., Crisp A. J. 1H nuclear magnetic resonance investigation of synovial fluid components in osteoarthritis, rheumatoid arthritis and traumatic effusions. Br J Rheumatol. 1989 Feb;28(1):23–27. doi: 10.1093/rheumatology/28.1.23. [DOI] [PubMed] [Google Scholar]
  57. Wright V. Oral gold for rheumatoid arthritis. Br Med J (Clin Res Ed) 1984 Oct 6;289(6449):858–859. doi: 10.1136/bmj.289.6449.858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. van der Heijde D. M., van Riel P. L., Nuver-Zwart I. H., Gribnau F. W., vad de Putte L. B. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989 May 13;1(8646):1036–1038. doi: 10.1016/s0140-6736(89)92442-2. [DOI] [PubMed] [Google Scholar]
  59. van der Heijde D. M., van Riel P. L., Nuver-Zwart I. H., van de Putte L. B. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet. 1990 Mar 3;335(8688):539–539. doi: 10.1016/0140-6736(90)90771-v. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES